Advertisement

CNS Drugs

, Volume 16, Issue 10, pp 715–720 | Cite as

Spotlight on Rizatriptan in Migraine

  • Keri Wellington
  • Blair Jarvis
Adis Spotlight

Abstract

Rizatriptan is an orally active serotonin 5-HT1 receptor agonist that potently and selectively binds to 5-HT1B/1D subtypes.

Earlier clinical trials demonstrated that rizatriptan 5 or 10mg is more effective than placebo at providing pain relief and a pain-free state, relieving associated symptoms of migraine, normalising functional ability and improving patient quality of life, and showed that rizatriptan provides faster freedom from pain and reduces nausea to a greater extent than oral sumatriptan.

More recently, rizatriptan 10mg was shown to be more effective than zolmitriptan 2.5mg or naratriptan 2.5mg at producing a pain-free state 2 hours postdose. Furthermore, compared with naratriptan, significantly more patients who received rizatriptan were pain free or had pain relief from 1 hour onwards. The number of patients with normal functional ability at 2 hours was significantly higher after rizatriptan than after naratriptan or zolmitriptan. Rizatriptan was also generally more effective than zolmitriptan or naratriptan at relieving migraine-associated symptoms.

Rizatriptan is generally well tolerated, and adverse events are usually mild and transient. The most common adverse events associated with rizatriptan in recent randomised trials were asthenia/fatigue, dizziness, somnolence and nausea. There was a trend towards a lower incidence of adverse events with rizatriptan compared with zolmitriptan (31.2 vs 38.8%). However, rizatriptan was associated with a significantly higher incidence of adverse events than naratriptan (39 vs 29%). The incidence of chest pain was similar after the administration of rizatriptan, zolmitriptan or naratriptan (2–4%).

In conclusion, rizatriptan is an effective drug for the acute treatment of moderate or severe migraine. Oral rizatriptan 5 and 10mg have shown greater efficacy than placebo in providing pain relief, an absence of pain, relief from associated symptoms, normal functional ability and an improvement in patient quality of 1 This Spotlight is derived from abstract and summary text of an Adis Drug Evaluation originally published in full in Drugs 2002; 62 (5): 817–840. life. Earlier results showed that rizatriptan provides faster freedom from pain and reduces nausea to a greater extent than oral sumatriptan. More recent studies have shown that rizatriptan 10mg provides faster pain relief and a higher percentage of patients with an absence of pain and normal functional ability at 2 hours than naratriptan 2.5mg or zolmitriptan 2.5mg. The efficacy of rizatriptan is retained when used in the long term, and the drug is generally well tolerated. Although well designed studies comparing rizatriptan with almotriptan, eletriptan and frovatriptan would further define the position of rizatriptan, current data suggest that rizatriptan should be considered as a first-line treatment option in the management of migraine.

Keywords

Migraine Sumatriptan Zolmitriptan Rizatriptan Almotriptan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The full text article in Drugs 2002; 62 (5): 817-840 was reviewed by: W.J. Becker, Division of Neurology, Foothills Medical Centre, Calgary, Alberta, Canada; G. Bussone, Third Neurological Division and Headache Centre, National Neurological Institute “C. Besta”, Milan, Italy; N.R. Cutler, California Clinical Trials Medical Group, Beverly Hills, Los Angeles, California, USA; C. Dahlöf, The Gothenburg Migraine Clinic, Sociala Huset, Gothenburg, Sweden; H.C. Diener, Department of Neurology, Klinik und Poliklinik fur Neurologie, Universitat Essen, Essen, Germany; L. Edvinsson, Department of Internal Medicine, University Hospital of Lund, Lund, Sweden; S. Evers, Department of Neurology, University of Munster, Munster, Germany; F. Facchinetti, Istituto di Clinica Osterica e Ginecologica, Universita Degli Stuid di Modena, Modena, Italy; K. Ghose, Department of Pharmacology, Faculty of Medicine, University of Otago, Dunedin, New Zealand; J. Sramek, California Clinical Trials Medical Group, Beverly Hills, Los Angeles, California, USA.

References

  1. 1.
    Pauwels PJ, Tardif S, Palmier C, et al. How efficacious are 5-HT1B/1D receptor ligands: an answer from GTPγS binding studies with stably transfected C6-glial cell lines. Neuropharmacology 1997; 36(4–5): 499–512PubMedCrossRefGoogle Scholar
  2. 2.
    Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/1D agonists: insights into migraine pathophysiology using rizatriptan. Neurology 2000; 55(Suppl. 2): S8–14PubMedGoogle Scholar
  3. 3.
    de Hoon JN, Willigers JM, Troost J, et al. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 2000; 68(4): 418–26PubMedCrossRefGoogle Scholar
  4. 4.
    Sciberras DG, Polvino WJ, Gertz BJ, et al. Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol 1997; 43: 49–54PubMedCrossRefGoogle Scholar
  5. 5.
    Sciberras DG, Majmudar N, Bowman AJ, et al. A study of the effects of MK-462 (rizatriptan), clonidine and sumatriptan on autonomic function. Br J Clin Pharmacol 1997; 43: 535PCrossRefGoogle Scholar
  6. 6.
    Goldberg MR, Lee Y, Vyas KP, et al. Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects. J Clin Pharmacol 2000; 40(1): 74–83PubMedCrossRefGoogle Scholar
  7. 7.
    Noveck RJ, Bialy GP, Bradstreet TE, et al. Effects of rizatriptan on blood pressure in hypertensive patients. Clin Pharmacol Ther 1998 Feb; 63: 184Google Scholar
  8. 8.
    Williamson DJ, Hill RG, Shepheard SL, et al. The anti-migraine 5-HT(lB/lD) agonist rizatriptan inhibits neurogenic durai vasodilation in anaesthetized guinea-pigs. Br J Pharmacol 2001; 133(7): 1029–34PubMedCrossRefGoogle Scholar
  9. 9.
    Williamson DJ, Shepheard SL, Hill RG, et al. The novel anti-migraine agent rizatriptan inhibits neurogenic durai vasodilation and extravasation. Eur J Pharmacol 1997; 328: 61–4PubMedCrossRefGoogle Scholar
  10. 10.
    Goldberg MR, Sciberras D, De Smet M, et al. Influence of β-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol 2001; 52(1): 69–76PubMedCrossRefGoogle Scholar
  11. 11.
    Merck and Co., Inc. Maxalt® and Maxalt-MLT® prescribing information: West Point, USA, 1998 [online]. Available from URL: http://www.merck.com [Accessed 2002 Mar 7]
  12. 12.
    Lee Y, Conroy JA, Stepanavage ME, et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol 1999; 47: 373–8PubMedCrossRefGoogle Scholar
  13. 13.
    Vyas KP, Halpin RA, Geer LA, et al. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab Dispos 2000; 28(1): 89–95PubMedGoogle Scholar
  14. 14.
    Goldberg MR, Lowry RC, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol 1999; 39: 192–9PubMedCrossRefGoogle Scholar
  15. 15.
    van Haarst AD, van Gerven JMA, Cohen AF, et al. The effects of moclobemide on the pharmacokinetics of the 5-HT(1B/1D) agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol 1999; 48: 190–6PubMedCrossRefGoogle Scholar
  16. 16.
    Musson DG, Birk KL, Panebianco DL, et al. Pharmacokinetics of rizatriptan in healthy elderly subjects. Int J Clin Pharmacol Ther 2001 Oct; 39(10): 447–52PubMedGoogle Scholar
  17. 17.
    Shadle CR, Liu G, Goldberg MR. A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. J Clin Pharmacol 2000; 40(3): 309–15PubMedCrossRefGoogle Scholar
  18. 18.
    Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine: the Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia 1999; 19: 525–30PubMedCrossRefGoogle Scholar
  19. 19.
    Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997; 17: 647–51PubMedCrossRefGoogle Scholar
  20. 20.
    Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence: a placebo-controlled, outpatient study: the Rizatriptan 022 Study Group. Headache 1998 Apr; 38: 281–7PubMedCrossRefGoogle Scholar
  21. 21.
    Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine: the Rizatriptan 046 Study Group. Headache 1998 Nov–Dec; 38: 737–47PubMedCrossRefGoogle Scholar
  22. 22.
    Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine: the Rizatriptan 030 Study Group. Headache 1998 Nov–Dec; 38: 748–55PubMedCrossRefGoogle Scholar
  23. 23.
    Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks: the Rizatriptan Multiple Attack Study Group. Neurology 1998; 51: 773–81PubMedCrossRefGoogle Scholar
  24. 24.
    Lines C, Visser WH, Vandormael K, et al. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache 1997 May; 37(5): 319–20Google Scholar
  25. 25.
    Pascual J, Vega P, Diener HC, et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine: the Rizatriptan-Zolmitriptan Study Group. Cephalalgia 2000; 20(5): 455–61Google Scholar
  26. 26.
    Bomhof M, Paz J, Legg N, et al. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine: the Rizatriptan-Naratriptan Study Group. Eur Neurol 1999; 42(3): 173–9Google Scholar
  27. 27.
    Lipton RB, Pascual J, Goadsby PJ, et al. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. Headache 2001; 41(8): 754–63PubMedCrossRefGoogle Scholar
  28. 28.
    Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001 Oct; 57: 1377–83PubMedCrossRefGoogle Scholar
  29. 29.
    Göbel H, Heinze A, Heinze-Kuhn K, et al. Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes. Headache 2001 Mar; 41(3): 264–70PubMedCrossRefGoogle Scholar
  30. 30.
    Cady R, Crawford G, Ahrens S, et al. Long-term efficacy and tolerability of rizatriptan wafers in migraine: the Rizatriptan-RPD Study Group. Med Gen Med 2001 Jun 1; 3(3): 1Google Scholar
  31. 31.
    Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 Nov 17; 358(9294): 1668–75PubMedCrossRefGoogle Scholar
  32. 32.
    Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res 2001; 4: 105–25Google Scholar
  33. 33.
    Silberstein SD, Massiou H, Le Jeunne C, et al. Rizatriptan in the treatment of menstrual migraine [abstract]. Obstet Gynecol 2000; 96(2): 237–42PubMedCrossRefGoogle Scholar
  34. 34.
    Silberstein SD, Massiou H, McCarroll KA, et al. Long-term efficacy of rizatriptan wafers in menstrual migraine. Cephalalgia 2001 May; 21: 423CrossRefGoogle Scholar
  35. 35.
    Dooley M, Faulds D. Rizatriptan: a review of its efficacy in the management of migraine. Drugs 1999 Oct; 58(4): 699-723PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Adis International LimitedNew Zealand

Personalised recommendations